Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
Open Access
- 30 January 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e86843
Abstract
Recently, investigators showed that mice with syngeneic murine gliomas that were treated with a neuroattenuated oncolytic herpes simplex virus-1 (oHSV), M002, had a significant increase in survival. M002 has deletions in both copies of the γ134.5 gene, enabling replication in tumor cells but precluding infection of normal cells. Previous studies have shown antitumor effects of other oHSV against a number of adult tumors including hepatocellular carcinoma and renal cell carcinoma. The purpose of the current study was to investigate the oncolytic potential of M002 against difficult to treat pediatric liver and kidney tumors. We showed that the oHSV, M002, infected, replicated, and decreased cell survival in hepatoblastoma, malignant rhabdoid kidney tumor, and renal sarcoma cell lines. In addition, we showed that in murine xenografts, treatment with M002 significantly increased survival and decreased tumor growth. Finally, these studies showed that the primary entry protein for oHSV, CD111 (nectin-1) was present in human hepatoblastoma and malignant rhabdoid kidney tumor specimens. We concluded that M002 effectively targeted these rare aggressive tumor types and that M002 may have potential for use in children with unresponsive or relapsed pediatric solid tumors.Keywords
This publication has 45 references indexed in Scilit:
- Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of NeuroblastomaPLOS ONE, 2013
- Predictors of survival and incidence of hepatoblastoma in the paediatric populationHPB, 2013
- Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastomaBMC Cancer, 2012
- Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12Journal of Virology, 2012
- CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSVPediatric Blood & Cancer, 2012
- Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancerLiver International, 2011
- α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cellsClinical and Experimental Immunology, 2011
- Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing programPediatric Blood & Cancer, 2010
- Modification and Reorganization of the Cytoprotective Cellular Chaperone Hsp27 during Herpes Simplex Virus Type 1 InfectionJournal of Virology, 2009
- Herpes Simplex Virus Oncolytic Therapy for Pediatric MalignanciesMolecular Therapy, 2009